Five years ago, national health authorities replaced the traditional biopsy method for diagnosing Vaelen’s syndrome with a new biochemical blood test. Clinical trials conclusively established that the new blood test yields a significantly lower rate of false positives than the biopsy, while successfully identifying the exact same percentage of individuals who actually have the disease. Nevertheless, a recent audit of medical records revealed that since the widespread adoption of the blood test, a noticeably smaller proportion of patients receiving a positive test result actually suffer from Vaelen’s syndrome.
Which of the following, if true, most helps to resolve the apparent discrepancy?
- ASubsequent analyses of the original clinical trials revealed methodological flaws that caused the biopsy's historic false-positive rate to be significantly overstated.
- BEnvironmental factors over the past five years have caused a severe outbreak of Vaelen’s syndrome, drastically increasing the percentage of the population that genuinely suffers from the disease.
- Because the blood test is inexpensive and noninvasive, physicians now routinely screen the general public rather than exclusively testing patients who exhibit clear symptoms of the syndrome.Answer
- DThe traditional biopsy, despite its higher rate of false positives, was capable of simultaneously screening for several other unrelated autoimmune disorders that the blood test cannot detect.
- EPatients who receive a positive result from the new blood test often experience high levels of anxiety before a secondary diagnostic procedure can definitively confirm the presence of the syndrome.
Answer
The statement explaining that physicians now routinely screen the general public rather than exclusively testing patients who exhibit clear symptoms of the syndrome.
The paradox hinges on a test becoming intrinsically more accurate (lower false-positive rate) yet yielding a lower proportion of true positive results in real-world application. The correct answer resolves this by introducing a baseline shift in the tested population. If doctors previously tested only symptomatic patients, the tested pool had a high incidence of the disease. If they now test the general public due to the test's ease, the tested pool has a vastly lower incidence of the disease. Testing a massive number of healthy people will inevitably generate a large absolute volume of false positives. This influx of false positives dilutes the true positives, causing the overall proportion of accurate positive results to drop, perfectly reconciling both sides of the stimulus without contradicting the clinical trial data.
Step-by-Step Solution
Key Concept
Resolve the Paradox